Sign In
Last checked at 
1 Dec 2025 11:00
1 December 2025
Convatec Group Plc("Convatec" or "the Company")
Total Voting Rights
In accordance with the UK Financial Conduct Authority's ("FCA") Disclosure and Transparency Rule 5.6.1R, the Company notifies the market that as at 30 November 2025:
1. The Company's issued share capital comprised 2,049,789,559 ordinary shares of 10p each, each with one vote.
2. 86,523,542 ordinary shares are held in treasury. These shares are not taken into consideration in relation to the payment of dividends and voting at shareholder meetings.
Accordingly, the total number of voting rights in the Company is 1,963,266,017. This figure may be used by shareholders as the denominator for the calculations by which to determine if they are required to notify their interest in, or a change to, their interest in the Company under the FCA's Disclosure and Transparency Rules.
There are 2,241,112 ordinary shares of the Company which have been purchased pursuant to the share buyback programme announced on 20 August 2025 which are in the course of the settlement process. Once settled, these shares will be held in treasury.
Contacts
The person responsible for making this announcement is James Kerton, Company Secretary, Convatec Group Plc: cosec@convatec.com
Media: MediaRelations@convatec.com
Investor Relations: IR@convatec.com
Convatec Group Plc's LEI code is 213800LS272L4FIDOH92
Classification: 2.5 Total number of voting rights and capital
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com
Follow the stocks
